Probiotic supplementation to slow kidney disease progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates whether probiotic supplementation can slow the progression of moderate to severe chronic kidney disease (CKD) by improving kidney function, reducing inflammation, and altering gut microbiota composition. Participants will be randomly assigned to receive either probiotics or a placebo for six months, with regular clinic visits for monitoring kidney function and potential side effects. The study aims to determine the safety and efficacy of probiotics in reducing harmful uremic toxins and improving overall health in CKD patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥ 18 years (both males and females).
* Diagnosed with Chronic Kidney Disease (CKD) Stage III or IV, confirmed by eGFR.
* Stable medical condition with no recent hospitalization for acute kidney injury or other serious illnesses.
* Not currently on probiotic supplementation or prebiotic therapy.
* Willing to provide informed consent and comply with the study protocol, including clinic visits and sample collection.

Exclusion Criteria:

* CKD Stage I, II, or V, or on dialysis.
* Currently using probiotics or prebiotics as part of their diet or treatment.
* History of active malignancy (cancer) or undergoing chemotherapy.
* Significant gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome, or recent GI surgery).
* Pregnant or breastfeeding women (due to safety concerns).
* Patients with autoimmune diseases (e.g., lupus, rheumatoid arthritis).
* Individuals on long-term antibiotic or anti-inflammatory medication that could interfere with microbiota composition.
* Individuals with severe behavioral or cognitive disorders that may prevent adherence to the study protocol.

Where it's running

• Urology and Nephrology Center, Mansoura University
  Al Mansurah, Dakahliya, Egypt Recruiting

Study contacts

• Study coordinator: Samar Elshahat Saleh
• Email: samarelshahat@mans.edu.eg
• Phone: 00201023771331

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Kodo Millet Porridge and Gut Health in Overweight and Obese Adults

  This study tests whether daily intake of Kodo millet porridge for 12 weeks can improve gut bacteria and metabolic health in adults who are overweight or obese.

  Recruiting Jss Medical College, Jss Academy of Higher Education and Research · Mysore, Karnataka · NCT07703371

• Living with CKD as a woman of childbearing age without dialysis or transplant

  This study asks how women aged 18 and up with chronic kidney disease, not on kidney replacement therapy, experience living with the condition.

  Recruiting University Hospital, Caen · Caen · NCT07690202

• Balcinrenone plus dapagliflozin vs dapagliflozin alone in CKD stages 3b-4

  This study tests whether balcinrenone combined with dapagliflozin works better than dapagliflozin alone in adults with CKD stage 3b–4.

  Recruiting at 33 sites Phase 3 AstraZeneca · Huntsville, Alabama and 477 other locations · NCT07624305

• AdiaVita regenerative therapy for chronic kidney disease

  This trial tests whether AdiaVita (umbilical cord blood stem cells and exosomes plus glutathione) can improve kidney function in adults with stage 2–4 chronic kidney disease.

  Recruiting Phase 1 Adia Med of Winter Park LLC · Winter Park, Florida · NCT07572890

• Multispecies synbiotic in people on hemodialysis

  This pilot study tests whether a multispecies synbiotic can alter gut microbes and reduce gut-derived toxins in adults on maintenance hemodialysis over 12 weeks.

  Recruiting Tungs' Taichung Metroharbour Hospital · Taichung, Wuqi District · NCT07461233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.